GTHX G1 Therapeutics Inc.

0  0%
Previous Close 26.27
Price To Book 2.9
Market Cap 984,262,109
Shares 37,467,153
Volume 1,856
Short Ratio
Av. Daily Volume 455,181

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data noted improvement in overall survival, overall response rates of 37-43%.Detailed data due later in 2019.
Triple-negative breast cancer
Phase 1/2 preliminary data due 3Q 2019.
Tagrisso and Lerociclib (G1T38)
EGFR mutation-positive non-small cell lung cancer (NSCLC)
Phase 2 additional data due 3Q 2019.
Trilaciclib plus Tecentriq
First-line small-cell lung cancer
Phase 1b additional data due 4Q 2019.
Lerociclib (G1T38) plus Faslodex
ER+ breast cancer
NDA filing due 2020.
Second/third-line small-cell lung cancer
Phase 2 patient-reported outcomes (PRO) data due at MASCC meeting June 21, 2019 at 3:40 p.m. PT.
Small-cell lung cancer
Phase 1/2 preliminary data due 3Q 2019.
ER+, HER2- breast cancer

Latest News

  1. Harry Boxer’s three biotech stocks on the move include Nektar Therapeutics
  2. Why new cancer trial data is good news for a Triangle pharma
  3. Company News For Jun 19, 2019
  4. Why SunPower, Snap, and G1 Therapeutics Jumped Today
  5. What's Behind The Rally In Small-Cap Biotech G1 Therapeutics?
  6. G1 Therapeutics Announces Updated Results from Phase 2 Trial of Trilaciclib in Combination with Chemotherapy Showed Statistically Significant Improvement in Overall Survival in Women with Metastatic Triple-Negative Breast Cancer
  7. G1 Therapeutics to Present Patient-Reported Outcomes (PRO) Data on Trilaciclib At Multinational Association of Supportive Care in Cancer (MASCC) And International Society of Oral Oncology (ISCOO) 2019 Annual Meeting
  8. G1 Therapeutics Announces Updates to Board of Directors
  9. G1 Therapeutics to Present at Raymond James Life Sciences and MedTech Conference
  10. G1 Therapeutics Presents Additional Phase 2 Data on Trilaciclib in Small Cell Lung Cancer at 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
  11. Edited Transcript of GTHX.O earnings conference call or presentation 9-May-19 8:30pm GMT
  12. G1 Therapeutics to Present Additional Trilaciclib Phase 2 Small Cell Lung Cancer Data at 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
  13. G1 Therapeutics, Inc. (GTHX) Q1 2019 Earnings Call Transcript
  14. G1 Therapeutics to Present at UBS Global Healthcare Conference
  15. Imagine Owning G1 Therapeutics (NASDAQ:GTHX) And Wondering If The 48% Share Price Slide Is Justified
  16. G1 Therapeutics Provides First Quarter 2019 Corporate and Financial Update
  17. Here’s What Hedge Funds Think About G1 Therapeutics, Inc. (GTHX)
  18. G1 Therapeutics to Report First Quarter Financial Results on May 9, 2019
  19. G1 Therapeutics aims to expand as it approaches NDA filing
  20. Why G1 Therapeutics Is Soaring 16% Today